Viridian Therapeutics to Present at the Ladenburg Thalmann 2021 Healthcare Conference
July 07 2021 - 8:00AM
Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical
company advancing new treatments for patients suffering from
serious diseases but underserved by today’s therapies, today
announced that Jonathan Violin, Ph.D., President and Chief
Executive Officer of Viridian, will present a company overview at
the virtual Ladenburg Thalmann 2021 Healthcare Conference taking
place July 13 – 14, 2021.
Event: |
Ladenburg Thalmann 2021 Healthcare Conference |
Date: |
Wednesday, July 14 |
Presentation Time: |
9:00 a.m. ET |
The webcast information for this event will be accessible on the
Events page under the Investors section of the Viridian
Therapeutics website at www.viridiantherapeutics.com. A replay
of the presentation will be archived on the website and available
for approximately 90 days following the live event.
About Viridian Therapeutics
Viridian Therapeutics is a biotechnology company advancing new
treatments for patients suffering from serious diseases but
underserved by today’s therapies. Viridian’s most advanced program,
VRDN-001, is an anti-IGF-1R monoclonal antibody in development for
TED, a debilitating auto-immune disease that causes inflammation
and fibrosis within the orbit of the eye which can cause double
vision, pain, and potential blindness. Patients with severe disease
often require multiple remedial surgeries to the orbit, eye
muscles, and eyelids. Viridian is based in Boulder, Colorado, and
Waltham, Massachusetts. Learn more about Viridian and its programs
at https://www.viridiantherapeutics.com/.
Follow us on Twitter @ViridianThera and on LinkedIn.
Viridian
Contacts:Investors:Dan FerryLifeSci
Advisors617-430-7576IR@viridiantherapeutics.com
Media:Darby PearsonVerge Scientific
Communications703-587-0831PR@viridiantherapeutics.com
Viridian Therapeutics (NASDAQ:VRDN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Viridian Therapeutics (NASDAQ:VRDN)
Historical Stock Chart
From Apr 2023 to Apr 2024